| 摘要: |
| 目的：观察宁泌泰胶囊联合盐酸坦洛新缓释片治疗非感染性Ⅲ型前列腺炎的临床疗效。方法：选择非感染性Ⅲ型前列腺炎患者100例，按随机数字表法分为研究组和对照组各50例。对照组给予盐酸坦洛新缓释片治疗，研究组在对照组基础上口服宁泌泰胶囊。评估2组治疗前后前列腺炎症指数评分（NIH-CPSI）、中医证候积分，并检测2组前列腺素2（PGE2）、前列腺液白细胞计数（EPS-WBC） 及肿瘤坏死因子-α（TNF-α） 水平。结果：治疗前，2组NIH-CPSI 总评分、疼痛或不适症状评分、排尿症状评分、生活质量评分比较，差异无统计学意义（P＞0.05）。治疗后，2组NIH-CPSI 总评分、疼痛或不适症状评分、排尿症状评分、生活质量评分较治疗前降低，且研究组NIH-CPSI总评分低于对照组，差异均有统计学意义（P＜0.05）。治疗后，2组中医证候总积分、主症积分、次症积分较治疗前降低，且研究组中医证候总积分、主症积分、次症积分低于对照组，差异均有统计学意义（P＜0.05）。治疗后，2组PGE2、EPS-WBC和TNF-α水平较治疗前降低，且研究组PGE2、EPS-WBC和TNF-α水平低于对照组，差异均有统计学意义（P＜0.05）。结论：宁泌泰胶囊联合盐酸坦洛新缓释片治疗非感染性Ⅲ型前列腺炎，能够显著改善患者临床症状，降低前列腺液PGE2、EPS-WBC及TNF-α水平，临床值得推广。 |
| 关键词: Ⅲ型前列腺炎 湿热瘀阻证 宁泌泰胶囊 盐酸坦洛新缓释片 前列腺炎症指数评分 前列腺素2 前列腺液白
细胞计数 肿瘤坏死因子-α |
| DOI： |
|
| 基金项目: |
|
| Clinical Study on Ningmitai Capsules Combined with Tamsulosin HydrochlorideSustained-release Tablets for Nonbacterial Type III Prostatitis |
| WANG Jia,ZHENG Jinhua,YE Tao,BAO Haoran |
| () |
| Abstract: |
| Abstract： Objective： To observe the clinical effect of Ningmitai capsules combined with tamsulosin hydrochloride
sustained-release tablets for nonbacterial type III prostatitis. Methods：A total of 100 cases of patients with nonbacterial type
III prostatitis were divided into the study group and the control group according to the random number table method，50 cases
in each group. The control group was treated with tamsulosin hydrochloride sustained-release tablets，and the study group
was additionally given oral administration of Ningmitai capsules based on the treatment of the control group. Before and after
treatment， the scores of NIH- Chronic Prostatitis Symptom Index(NIH- CPSI) and Chinese medicine syndromes in the two
groups were evaluated， and the levels of prostaglandin E2(PGE2)， white blood cell count in expressed prostatic secretion
(EPS- WBC) and tumor necrosis factor- α(TNF- α) in the two groups were detected. Results：Before treatment，compared
the total scores of NIH- CPSI and the scores of pain， uncomfortable symptoms， voiding symptoms and quality of life
between the two groups，there was no significance in the difference(P＞0.05). After treatment，the total scores of NIH-CPSI
and the scores of pain，uncomfortable symptoms，voiding symptoms and quality of life in the two groups were all decreased
when compared with those before treatment，and the total score of NIH-CPSI in the study group was lower than that in the
control group，differences being significant(P＜0.05). After treatment，the total scores of Chinese medicine symptoms and
the scores of main and secondary symptoms in the two groups were decreased when compared with those before
treatment，and the above scores in the study group were lower than those in the control group，differences being significant
(P＜0.05). After treatment，the levels of PGE2，EPS-WBC and TNF-α in the two groups were decreased when compared
with those before treatment，and the above levels in the study group were lower than those in the control group，differences being significant(P＜0.05). Conclusion：The therapy of Ningmitai capsules combined with tamoxin hydrochloride sustainedrelease
tablets can significantly improve the clinical symptoms of patients with nonbacterial type III prostatitis，and reduce the
levels of PGE2，EPS-WBC and TNF-α in expressed prostatic secretion，which is worthy of clinical promotion. |
| Key words: Keywords ： Type III prostatitis Dampness- heat stasis obstruction syndrome Ningmitai capsules Tamsulosin
hydrochloride sustained-release tablets NIH-Chronic Prostatitis Symptom Index Prostaglandin E2 White blood cell count
in expressed prostatic secretion Tumor necrosis factor-α |
